Table 1.
Baseline demographics of patients
| Characteristic | REACT cohort | FH inclusion | ASCVD inclusion | P value FH vs ASCVD |
|---|---|---|---|---|
| N | 195 | 109 | 86 | |
| Men/women | 109/86 | 61/48 | 48/38 | 0.98 |
| Age, y (mean ± SD) [range] | 63 ± 12 [28-89] | 60 ± 12 [28-87] | 66 ± 10 [40-89] | < 0.001 |
| BMI, kg/m2 (mean ± SD) | 28.9 ± 5.1 | 29.0 ± 5.2 | 28.7 ± 4.85 | 0.64 |
| Cardiovascular disease reported for inclusion (%) | 46.2% | 3.7% | 100% | < 0.001 |
| Family history of ASCVD (%) | 59.5% | 74.3% | 40.7% | < 0.001 |
| Systemic hypertension (%) | 62.1% | 51.4% | 75.6% | < 0.001 |
| Type 2 diabetes (%) | 26.2% | 21.1% | 32.6% | 0.07 |
| Smoking (past and current) (%) | 37.9% | 34.9% | 41.9% | 0.32 |
| Total cholesterol, mmol/L (mean ± SD) | 6.34 ± 1.18 | 6.50 ± 1.27 | 6.14 ± 1.02 | 0.03 |
| LDL-C, mmol/L (mean ± SD) | 4.26 ± 0.94 | 4.46 ± 1.00 | 4.02 ± 0.81 | < 0.001 |
| HDL-C, mmol/L (mean ± SD) | 1.29 ± 0.49 | 1.30 ± 0.43 | 1.28 ± 0.57 | 0.79 |
| Triglycerides, mmol/L (mean ± SD) | 2.29 ± 2.00 | 2.26 ± 2.21 | 2.32 ± 1.72 | 0.86 |
| Imputed baseline LDL-C (mean ± SD) | 7.04 ± 2.90 | 7.53 ± 2.93 | 6.41 ± 2.75 | 0.007 |
| Lipid-lowering therapy∗ (%) | 76.9% | 78.0% | 75.6% | 0.69 |
| Reported goal-inhibiting statin intolerance (%) | 64.1% | 66.10% | 61.6% | 0.52 |
| Any statin (%) | 60.0% | 62.4% | 57.0% | 0.44 |
| Any statin + ezetimibe 10 mg/d (%) | 15.9% | 15.6% | 16.3% | 0.90 |
| High-intensity statin (%)† | 35.4% | 36.7% | 33.7% | 0.67 |
| Moderate-intensity statin (%)† | 19.0% | 21.1% | 16.3% | 0.39 |
| Low-intensity statin (%)† | 5.6% | 4.6% | 7.0% | 0.47 |
ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density cholesterol lipoprotein; REACT, Relating Evidence to Achieve Cholesterol Targets; SD, standard deviation.
Bold values denote statistical significance at the P < 0.05 level.
Any lipid-lowering therapy includes statins, ezetimibe, bile acid sequestrants, niacin, fibrates, and omega-3.
High-intensity statin includes atorvastatin 40-80 mg and rosuvastatin 20-40 mg; moderate-intensity statin includes atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40-80 mg, and fluvastatin 40 mg; low-intensity statin includes simvastatin 10 mg, pravastatin 5-20 mg, and fluvastatin 20 mg.